The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
